Published in Ann Oncol on November 01, 2003
Effects of young age at presentation on survival in breast cancer. BMC Cancer (2006) 2.16
Breast cancer in young women and its impact on reproductive function. Hum Reprod Update (2009) 1.40
Surgical management of early stage invasive breast cancer: a practice guideline. Can J Surg (2005) 1.12
The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol (2011) 1.09
Preoperative localization and surgical margins in conservative breast surgery. Int J Surg Oncol (2013) 1.08
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Oncoplastic surgical techniques for personalized breast conserving surgery in breast cancer patient with small to moderate sized breast. J Breast Cancer (2011) 0.97
Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. Oncoimmunology (2015) 0.93
Minimally invasive ablative therapies for invasive breast carcinomas: an overview of current literature. World J Surg (2007) 0.90
Intraoperative Radiotherapy Versus Whole-Breast External Beam Radiotherapy in Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.83
The impact of local and regional recurrence on distant metastasis and survival in patients treated with breast conservation therapy. J Breast Cancer (2011) 0.81
Mammographic findings after intraoperative radiotherapy of the breast. Radiol Res Pract (2012) 0.81
Results of breast conserving surgery in clinical stage I-II breast carcinoma. Indian J Surg (2009) 0.80
Safe negative margin width in breast conservative therapy: results from a population with a high percentage of negative prognostic factors. World J Surg (2014) 0.80
Comparison of recurrence and survival rates after breast-conserving therapy and mastectomy in young women with breast cancer. Curr Oncol (2013) 0.80
Partial breast irradiation versus whole breast radiotherapy for early-stage breast cancer: a decision analysis. Int J Radiat Oncol Biol Phys (2007) 0.78
Two distinct β-sheet structures in Italian-mutant amyloid-beta fibrils: a potential link to different clinical phenotypes. Cell Mol Life Sci (2015) 0.76
Meta-analytic comparison of randomized and nonrandomized studies of breast cancer surgery. Can J Surg (2012) 0.76
Multidisciplinary approach of early breast cancer: the biology applied to radiation oncology. Radiat Oncol (2010) 0.76
Local relapse after breast-conserving surgery and radiotherapy: effects on survival parameters. Strahlenther Onkol (2009) 0.75
Radiotherapy of early breast cancer in scleroderma patients: our experience with four cases and a short review of the literature. Breast Cancer (Dove Med Press) (2012) 0.75
Late local recurrences in a randomized trial comparing conservative treatment with total mastectomy in early breast cancer patients: the impact of receptor status on local relapse. Ann Oncol (2004) 0.75
Breast conservation in patients of 35 years or younger. Ann Oncol (2004) 0.75
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med (2001) 5.71
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92
Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol (1988) 3.84
Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol (2007) 3.59
EBV gene expression in an NPC-related tumour. EMBO J (1989) 2.94
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol (1990) 2.58
Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer (1988) 2.46
Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol (1990) 2.43
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol (1992) 2.14
Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J Sci Am (1997) 2.09
Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol (1996) 2.08
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer (1996) 2.06
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J Virol (1991) 1.91
ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther (2010) 1.83
Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol (2004) 1.79
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol (1998) 1.75
Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy: experience of the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys (1985) 1.74
Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci U S A (1990) 1.72
Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer (1984) 1.71
Identical reactivity of monoclonal antibodies HNK-1 and NC-1: conservation in vertebrates on cells derived from the neural primordium and on some leukocytes. Cell Differ (1984) 1.70
Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J Immunol (1987) 1.60
Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol (1989) 1.60
Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc Natl Acad Sci U S A (1986) 1.56
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol (2005) 1.54
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody. Science (1983) 1.51
Risk factors for failure of immediate breast reconstruction with prosthesis after total mastectomy for breast cancer. Cancer (1992) 1.46
Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation. J Virol (1992) 1.44
Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging (2006) 1.41
Mutations introduced along the HTLV-I envelope gene result in a non-functional protein: a basis for envelope conservation? EMBO J (1990) 1.40
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest (1997) 1.39
Possible cohort effects in studies on oral contraceptive use and breast cancer. Br J Cancer (1985) 1.38
HNK-1 antibody detects an antigen expressed on neuroectodermal cells. J Exp Med (1983) 1.34
Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res (1993) 1.31
Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer (2003) 1.29
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol (2007) 1.29
Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level. J Exp Med (1979) 1.27
Ductal carcinoma in situ: MR imaging-histopathologic correlation. Radiology (1995) 1.27
Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production. Eur J Immunol (1980) 1.25
Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proc Natl Acad Sci U S A (1981) 1.25
Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor. Proc Natl Acad Sci U S A (1987) 1.25
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol (1998) 1.23
IL 2 receptor induction on human T lymphocytes: role for IL 2 and monocytes. J Immunol (1985) 1.22
Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res (1987) 1.21
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol (1994) 1.21
Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein. J Virol (1994) 1.19
T cell activation via CD2 [T, gp50]: the role of accessory cells in activating resting T cells via CD2. J Immunol (1986) 1.19
[Could treatments with beta-blockers be associated with a reduction in cancer risk?]. Rev Epidemiol Sante Publique (2004) 1.19
Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol (2000) 1.17
Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production. J Exp Med (2001) 1.16
Is it useful to remove internal mammary nodes in operable breast cancer? Eur J Surg Oncol (1987) 1.15
The effects of steroids on T cells. Transplant Proc (1975) 1.15
Quinolone-induced differential modification of IL-1 alpha and IL-1 beta production by LPS-stimulated human monocytes. Cell Immunol (1990) 1.14
Risk factors for breast cancer according to age at diagnosis in a French case-control study. J Clin Epidemiol (1990) 1.14
Retained surgical sponge or gossypiboma of the breast. Eur J Radiol (2002) 1.13
The cytoplasmic domain of the human T-cell leukemia virus type I envelope can modulate envelope functions in a cell type-dependent manner. J Virol (1993) 1.13
Intracellular signaling events in CD77-mediated apoptosis of Burkitt's lymphoma cells. Blood (1997) 1.11
Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci U S A (1994) 1.11
Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1 alpha. Proc Natl Acad Sci U S A (1987) 1.10
Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat (2000) 1.09
Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol (1992) 1.09
Use of a monoclonal antibody (GA3) to demonstrate lineage restricted O-glycosylation on leukosialin during terminal erythroid differentiation. Blood (1988) 1.08
C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet (1987) 1.08
Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line. J Immunol (1986) 1.07
European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Ann Chir Gynaecol (1998) 1.07
Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene (1998) 1.06
Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol (2013) 1.06
Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J Gen Virol (1995) 1.06
Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int J Cancer (1987) 1.05
Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction. Mol Immunol (1990) 1.05
CD77: an antigen of germinal center B cells entering apoptosis. Eur J Immunol (1991) 1.03
Exosomes for cancer immunotherapy. Ann Oncol (2004) 1.03
Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2. J Virol (1989) 1.02
Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst (1993) 1.01
Variation in the interaction between familial and reproductive factors on the risk of breast cancer according to age, menopausal status, and degree of familiality. Int J Epidemiol (2000) 1.01
Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol (1994) 1.01
Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res (1999) 1.00
Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer (2009) 1.00
Consumption of dairy produce and alcohol in a case-control study of breast cancer. J Natl Cancer Inst (1986) 1.00
Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Int J Cancer (1999) 0.99
Enzymatic and organizational difference in expression of a Burkitt lymphoma-associated antigen (globotriaosylceramide) in Burkitt lymphoma and lymphoblastoid cell lines. J Biol Chem (1984) 0.98
c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer (2001) 0.98
High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells. Virology (1997) 0.97
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene (2000) 0.96